Financhill
Sell
17

BIOLQ Quote, Financials, Valuation and Earnings

Last price:
$0.0100
Seasonality move :
-4.02%
Day range:
$0.0092 - $0.0096
52-week range:
$0.0040 - $0.1560
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.00x
P/B ratio:
--
Volume:
4.1K
Avg. volume:
54.8K
1-year change:
-93.78%
Market cap:
$336.7K
Revenue:
$49.2M
EPS (TTM):
-$2.04

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BIOLQ
Biolase
$13.5M -$0.01 3.78% -99.71% $1.2000
ALGN
Align Technology
$975.8M $1.99 2.9% 100.44% $227.30
MLSS
Milestone Scientific
$2.5M -$0.01 40.26% -50% $2.13
NVST
Envista Holdings
$606.4M $0.20 0.62% 46.34% $19.04
SOLV
Solventum
$2B $1.22 1.89% 185.16% $82.17
XRAY
Dentsply Sirona
$853.9M $0.30 -5.77% 234.18% $18.14
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BIOLQ
Biolase
$0.0092 $1.2000 $336.7K -- $0.00 0% 0.00x
ALGN
Align Technology
$188.07 $227.30 $13.6B 34.26x $0.00 0% 3.52x
MLSS
Milestone Scientific
$0.92 $2.13 $71.8M -- $0.00 0% 8.51x
NVST
Envista Holdings
$19.14 $19.04 $3.2B -- $0.00 0% 1.32x
SOLV
Solventum
$75.55 $82.17 $13.1B 34.98x $0.00 0% 1.58x
XRAY
Dentsply Sirona
$16.41 $18.14 $3.3B -- $0.16 3.9% 0.89x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BIOLQ
Biolase
142.17% -4.491 714.45% 0.23x
ALGN
Align Technology
-- 2.173 -- 0.99x
MLSS
Milestone Scientific
-- 1.937 -- 0.62x
NVST
Envista Holdings
31.74% 1.812 47.7% 1.68x
SOLV
Solventum
70.81% 0.887 60.15% 0.64x
XRAY
Dentsply Sirona
53.74% 1.023 78.42% 0.56x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BIOLQ
Biolase
$4.4M -$695K -129.74% -21668.17% -7.48% -$4.5M
ALGN
Align Technology
$680.1M $135.3M 10.72% 10.72% 13.81% $27.4M
MLSS
Milestone Scientific
$1.6M -$2M -79.98% -79.98% -89.49% -$1M
NVST
Envista Holdings
$336M $47.4M -24.02% -34.78% 6.21% -$5.6M
SOLV
Solventum
$1.1B $152M 3.34% 11.75% 6.86% -$80M
XRAY
Dentsply Sirona
$466M $70M -19.2% -35.57% 7.17% -$12M

Biolase vs. Competitors

  • Which has Higher Returns BIOLQ or ALGN?

    Align Technology has a net margin of -13.16% compared to Biolase's net margin of 9.52%. Biolase's return on equity of -21668.17% beat Align Technology's return on equity of 10.72%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOLQ
    Biolase
    40.39% -$0.04 $12.4M
    ALGN
    Align Technology
    69.45% $1.27 $3.8B
  • What do Analysts Say About BIOLQ or ALGN?

    Biolase has a consensus price target of $1.2000, signalling upside risk potential of 21639.13%. On the other hand Align Technology has an analysts' consensus of $227.30 which suggests that it could grow by 20.86%. Given that Biolase has higher upside potential than Align Technology, analysts believe Biolase is more attractive than Align Technology.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOLQ
    Biolase
    1 1 0
    ALGN
    Align Technology
    8 6 0
  • Is BIOLQ or ALGN More Risky?

    Biolase has a beta of -0.033, which suggesting that the stock is 103.32% less volatile than S&P 500. In comparison Align Technology has a beta of 1.643, suggesting its more volatile than the S&P 500 by 64.323%.

  • Which is a Better Dividend Stock BIOLQ or ALGN?

    Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Align Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Align Technology pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOLQ or ALGN?

    Biolase quarterly revenues are $10.9M, which are smaller than Align Technology quarterly revenues of $979.3M. Biolase's net income of -$1.4M is lower than Align Technology's net income of $93.2M. Notably, Biolase's price-to-earnings ratio is -- while Align Technology's PE ratio is 34.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 3.52x for Align Technology. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOLQ
    Biolase
    0.00x -- $10.9M -$1.4M
    ALGN
    Align Technology
    3.52x 34.26x $979.3M $93.2M
  • Which has Higher Returns BIOLQ or MLSS?

    Milestone Scientific has a net margin of -13.16% compared to Biolase's net margin of -89.35%. Biolase's return on equity of -21668.17% beat Milestone Scientific's return on equity of -79.98%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOLQ
    Biolase
    40.39% -$0.04 $12.4M
    MLSS
    Milestone Scientific
    73.8% -$0.02 $4.5M
  • What do Analysts Say About BIOLQ or MLSS?

    Biolase has a consensus price target of $1.2000, signalling upside risk potential of 21639.13%. On the other hand Milestone Scientific has an analysts' consensus of $2.13 which suggests that it could grow by 132.24%. Given that Biolase has higher upside potential than Milestone Scientific, analysts believe Biolase is more attractive than Milestone Scientific.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOLQ
    Biolase
    1 1 0
    MLSS
    Milestone Scientific
    1 0 0
  • Is BIOLQ or MLSS More Risky?

    Biolase has a beta of -0.033, which suggesting that the stock is 103.32% less volatile than S&P 500. In comparison Milestone Scientific has a beta of 0.902, suggesting its less volatile than the S&P 500 by 9.838%.

  • Which is a Better Dividend Stock BIOLQ or MLSS?

    Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Milestone Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Milestone Scientific pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOLQ or MLSS?

    Biolase quarterly revenues are $10.9M, which are larger than Milestone Scientific quarterly revenues of $2.2M. Biolase's net income of -$1.4M is higher than Milestone Scientific's net income of -$2M. Notably, Biolase's price-to-earnings ratio is -- while Milestone Scientific's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 8.51x for Milestone Scientific. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOLQ
    Biolase
    0.00x -- $10.9M -$1.4M
    MLSS
    Milestone Scientific
    8.51x -- $2.2M -$2M
  • Which has Higher Returns BIOLQ or NVST?

    Envista Holdings has a net margin of -13.16% compared to Biolase's net margin of 2.92%. Biolase's return on equity of -21668.17% beat Envista Holdings's return on equity of -34.78%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOLQ
    Biolase
    40.39% -$0.04 $12.4M
    NVST
    Envista Holdings
    54.47% $0.10 $4.4B
  • What do Analysts Say About BIOLQ or NVST?

    Biolase has a consensus price target of $1.2000, signalling upside risk potential of 21639.13%. On the other hand Envista Holdings has an analysts' consensus of $19.04 which suggests that it could fall by -0.51%. Given that Biolase has higher upside potential than Envista Holdings, analysts believe Biolase is more attractive than Envista Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOLQ
    Biolase
    1 1 0
    NVST
    Envista Holdings
    4 9 1
  • Is BIOLQ or NVST More Risky?

    Biolase has a beta of -0.033, which suggesting that the stock is 103.32% less volatile than S&P 500. In comparison Envista Holdings has a beta of 0.995, suggesting its less volatile than the S&P 500 by 0.5%.

  • Which is a Better Dividend Stock BIOLQ or NVST?

    Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Envista Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Envista Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOLQ or NVST?

    Biolase quarterly revenues are $10.9M, which are smaller than Envista Holdings quarterly revenues of $616.9M. Biolase's net income of -$1.4M is lower than Envista Holdings's net income of $18M. Notably, Biolase's price-to-earnings ratio is -- while Envista Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 1.32x for Envista Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOLQ
    Biolase
    0.00x -- $10.9M -$1.4M
    NVST
    Envista Holdings
    1.32x -- $616.9M $18M
  • Which has Higher Returns BIOLQ or SOLV?

    Solventum has a net margin of -13.16% compared to Biolase's net margin of 6.62%. Biolase's return on equity of -21668.17% beat Solventum's return on equity of 11.75%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOLQ
    Biolase
    40.39% -$0.04 $12.4M
    SOLV
    Solventum
    53.82% $0.78 $11.2B
  • What do Analysts Say About BIOLQ or SOLV?

    Biolase has a consensus price target of $1.2000, signalling upside risk potential of 21639.13%. On the other hand Solventum has an analysts' consensus of $82.17 which suggests that it could grow by 8.76%. Given that Biolase has higher upside potential than Solventum, analysts believe Biolase is more attractive than Solventum.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOLQ
    Biolase
    1 1 0
    SOLV
    Solventum
    1 8 0
  • Is BIOLQ or SOLV More Risky?

    Biolase has a beta of -0.033, which suggesting that the stock is 103.32% less volatile than S&P 500. In comparison Solventum has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock BIOLQ or SOLV?

    Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solventum offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biolase pays -- of its earnings as a dividend. Solventum pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BIOLQ or SOLV?

    Biolase quarterly revenues are $10.9M, which are smaller than Solventum quarterly revenues of $2.1B. Biolase's net income of -$1.4M is lower than Solventum's net income of $137M. Notably, Biolase's price-to-earnings ratio is -- while Solventum's PE ratio is 34.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 1.58x for Solventum. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOLQ
    Biolase
    0.00x -- $10.9M -$1.4M
    SOLV
    Solventum
    1.58x 34.98x $2.1B $137M
  • Which has Higher Returns BIOLQ or XRAY?

    Dentsply Sirona has a net margin of -13.16% compared to Biolase's net margin of 2.28%. Biolase's return on equity of -21668.17% beat Dentsply Sirona's return on equity of -35.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    BIOLQ
    Biolase
    40.39% -$0.04 $12.4M
    XRAY
    Dentsply Sirona
    53.02% $0.10 $4.3B
  • What do Analysts Say About BIOLQ or XRAY?

    Biolase has a consensus price target of $1.2000, signalling upside risk potential of 21639.13%. On the other hand Dentsply Sirona has an analysts' consensus of $18.14 which suggests that it could grow by 10.56%. Given that Biolase has higher upside potential than Dentsply Sirona, analysts believe Biolase is more attractive than Dentsply Sirona.

    Company Buy Ratings Hold Ratings Sell Ratings
    BIOLQ
    Biolase
    1 1 0
    XRAY
    Dentsply Sirona
    2 13 0
  • Is BIOLQ or XRAY More Risky?

    Biolase has a beta of -0.033, which suggesting that the stock is 103.32% less volatile than S&P 500. In comparison Dentsply Sirona has a beta of 0.948, suggesting its less volatile than the S&P 500 by 5.215%.

  • Which is a Better Dividend Stock BIOLQ or XRAY?

    Biolase has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona offers a yield of 3.9% to investors and pays a quarterly dividend of $0.16 per share. Biolase pays -- of its earnings as a dividend. Dentsply Sirona pays out -13.85% of its earnings as a dividend.

  • Which has Better Financial Ratios BIOLQ or XRAY?

    Biolase quarterly revenues are $10.9M, which are smaller than Dentsply Sirona quarterly revenues of $879M. Biolase's net income of -$1.4M is lower than Dentsply Sirona's net income of $20M. Notably, Biolase's price-to-earnings ratio is -- while Dentsply Sirona's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biolase is 0.00x versus 0.89x for Dentsply Sirona. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BIOLQ
    Biolase
    0.00x -- $10.9M -$1.4M
    XRAY
    Dentsply Sirona
    0.89x -- $879M $20M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Planet Labs’ Stock Go Next?
Where Will Planet Labs’ Stock Go Next?

On 4 June 2025 Planet reported Q1 FY 2026 revenue of $66.3 million, up 10% year over…

Where Will VICI Properties Be in 5 Years?
Where Will VICI Properties Be in 5 Years?

VICI Properties (NYSE:VICI) is a real estate investment trust focused…

Where Will Exxon Stock Be in 5 Years?
Where Will Exxon Stock Be in 5 Years?

For sure Exxon Mobil (NYSE: XOM) is no hyped-up AI…

Stock Ideas

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 49x

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 40x

Sell
43
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
75
INSM alert for Jun 11

Insmed [INSM] is up 7.75% over the past day.

Sell
25
AAON alert for Jun 11

AAON [AAON] is down 3.49% over the past day.

Buy
58
EXOD alert for Jun 11

Exodus Movement [EXOD] is down 8.21% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock